包装 | 价格(元) |
10mM (in 1mL DMSO) | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
Cell lines | HL-1 cardiomyocytes |
Preparation method | The solubility of this compound in DMSO is >23.85mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition | 5 μM;12 hr |
Applications | In HL-1 cardiomyocytes, suppression of eIF4E-induced translation by 4E1RCat contributed to suppression of MCL-1 expression. |
Animal models | mice bearing Pten+/-Eμ-Myc or Tsc2+/-Eμ-Myc lymphomas |
Dosage form | 4E1RCat (15 mg/kg daily for 5 d); doxorubicin (once at 10 mg/kg on day two) intraperitoneal (i.p.) injection in 5.2% PEG 400/ 5.2% Tween 80 |
Application | In mice bearing Pten+/-Eμ-Myc or Tsc2+/-Eμ-Myc lymphomas, 4E1RCat and doxorubicin (Dox) synergized and extended tumor-free remissions for up to 14d, unlikely due to 4E1RCat nonspecifically increasing Dxr efficacy. 4E1RCat + Dxr increased the number of apoptotic cells. 4E1RCat decreased levels of Mcl-1 in tumors. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
产品描述 | 4E1RCat is a dual inhibitor of eIF4E:4E-BP1 and eIF4E:eIF4G interaction, and inhibits the binding of eIF4G to eIF4E with IC50 of 3.2 μM. |